Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criteria for Tolvaptan

Eiji Higashihara\textsuperscript{a, b} Shigeo Horie\textsuperscript{c} Satoru Muto\textsuperscript{c} Haruna Kawano\textsuperscript{c} Mitsuro Tambo\textsuperscript{b} Tsuyoshi Yamaguchi\textsuperscript{b} Satoru Taguchi\textsuperscript{b} Shinya Kaname\textsuperscript{d} Kenich Yokoyama\textsuperscript{e} Tatsuya Yoshioka\textsuperscript{e} Toshihito Furukawa\textsuperscript{f} Hiroshi Fukuhara\textsuperscript{c}

\textsuperscript{a}Department of Hereditary Kidney Disease Research, Kyorin University School of Medicine, Tokyo, Japan; \textsuperscript{b}Department of Urology, Kyorin University School of Medicine, Tokyo, Japan; \textsuperscript{c}Department of Urology, Juntendo University School of Medicine, Tokyo, Japan; \textsuperscript{d}Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; \textsuperscript{e}Department of Radiology, Kyorin University School of Medicine, Tokyo, Japan; \textsuperscript{f}Biostatistical Research Co., Ltd., Tokyo, Japan

**Keywords**

Autosomal dominant polycystic kidney disease · Total kidney volume · Height-adjusted TKV · Estimated HtTKV growth rate · End-stage renal disease · Tolvaptan · Guidelines

**Abstract**

**Background:** Tolvaptan was approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). However, the official indication of “rapidly progressive disease” is described differently in the clinical guidelines. We aim to define “rapidly progressive disease” by risk of ESRD, which is evaluated using estimated height-adjusted total kidney volume (HtTKV) growth rate. **Methods:** The risk of ESRD was retrospectively analyzed in 617 initially non-ESRD adults with ADPKD and observed with standard of care between 2007 and 2018. The estimated annual growth rate of the HtTKV, termed as eHTKV-α (%/year), is derived from the following equation: \[\text{HtTKV at age } t = K(1 + \text{eHTKV-α/100})^t\], where \(K = 150 \text{ mL/m}\) is used in Mayo Imaging Classification and \(K = 130 \text{ mL/m}\) is proposed for individually stable eHTKV-α value from baseline. The accuracy of eHTKV-α to predict ESRD for censored ages was analyzed using time-dependent receiver-operating characteristic curves (ROC). The cutoff point of initially measured eHTKV-α to predict ESRD was assessed using Kaplan-Meier and Cox’s proportional hazards models. Performance characteristics of the cutoff point for censored ages were calculated using time-dependent ROC and validated by the bootstrap method. **Results:** The area under the time-dependent ROC of eHTKV-α to predict ESRD at age 65 was 0.89 ± 0.04 (\(K = 130\)). The mean renal survival was less than 70 years at eHTKV-α ≥4.0%/year (\(K = 130\)). Mean renal survival was approximately 12 years shorter, and hazard ratio of ESRD was more than 5-time higher at this cutoff point than at lower point. Time-dependent sensitivity for age 65 and cutoff point of 4.0%/year (\(K = 130\)) was 93.4 ± 0.3%. Between cutoff points ≥4.0%/year (\(K = 130\)) and ≥3.5%/year (\(K = 150\)), there was no significant difference in performance characteristics and accuracy to predict ESRD. **Conclusion:**
sion: eHTKV-α well predicts ESRD. Initially, measured eHTKV-α ≥4.0%/year (K = 130) defines high-risk ESRD. Without additional conditions, a single eHTKV-α cutoff point identifies subjects that are most likely to benefit from tolvaptan.

© 2020 The Author(s)
Published by S. Karger AG, Basel

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited kidney disease and fourth leading cause of ESRD [1, 2]. Approximately 70% of patients with ADPKD progress to ESRD at around the age of 60–70 years [3, 4]. The wide variations in ages of reaching ESRD are accounted for by different rates of total kidney volume (TKV) enlargement [1, 5–7]. The Tolvaptan Efficacy and Safety in Management of ADPKD and its Outcomes (TEMPO) 3:4 trial reported beneficial effects of tolvaptan, a selective vasopressin V2-receptor antagonist, to slow the growth rate in TKV and the decline rate in kidney function in patients with ADPKD [8].

In acknowledgment of the TEMPO 3:4 results, the Ministry of Health, Labor, and Welfare in Japan approved tolvaptan in March 2014 for the treatment of patients with ADPKD, TKV of 750 mL or more, and TKV growth rate of 5%/year or more [9, 10]. In February 2015, Health Canada approved tolvaptan for patients with ADPKD with no initial specification [11]. The European Medical Agencies followed in May 2015, approving tolvaptan for the treatment of ADPKD patients with evidence of rapid disease progression [12]. After confirming tolvaptan benefits in later-stage ADPKD [13], the US Food and Drug Administration approved the use of tolvaptan as a treatment in patients classified as 1C by Canadian guidelines [18]. Five Mayo Classes (eHTKV-α of −1.5, 1.5–3.0, 3.0–4.5, 4.5–6.0, and 6.0–%)/year) are categorized as slow, intermediate, and rapid progression [6]. Hence, class 1C (3.0–4.5%/year) is originally classified into the intermediate progression category.

As eGFR decline is individually variable and nonlinear in a substantial fraction [19], the risk of ESRD is adopted as a more reliable outcome measure of rapidly progressive disease. We aimed to specify an eHTKV-α cutoff point to more precisely define subjects at high-risk of ESRD.

Patients and Methods

Study Design

The present study aimed to identify “rapidly progressive ADPKD” by risk of ESRD using eHTKV-α data from 2 Japanese ADPKD cohorts. Two cutoff points of eHTKV-α were calculated using K = 130 mL/m and K = 150 mL/m for comparison of accuracy and performance. The accuracy of eHTKV-α for predicting ESRD was examined by the area under the time-dependent receiver-operating characteristic curve (ROC). Preliminary cutoff points of eHTKV-α to predict the eGFR declining to 15 mL/min/1.73 m² at censored ages 60, 65, and 70 were calculated. Censored ages were selected because the incidence of renal replacement therapy (RRT) is high from age 50 to 75 in 2006–2010 ERA-EDTA data [4].

The mean renal survival and hazard ratio of ESRD were compared among several subgroups divided variably around preliminary cutoff points of eHTKV-α to identify those to predict high-risk ESRD. Then, performance characteristics of eHTKV-α as a predictor of ESRD for the cutoff points and for different censored ages were estimated using time-dependent ROC analysis and vali-

882 Am J Nephrol 2020;51:881–890
DOI: 10.1159/000511797

Higashihara et al.
### Table 1. Demographic data according to Mayo Class (K = 130 mL/m used)

| Mayo Class Limit of eHTKV-α (%/year) | Total | 1A | 1B | 1C | 1D | 1E | p-value |
|-----------------------------------|-------|----|----|----|----|----|---------|
|                                   | mean  | SD | ≤1.5 | 1.5–3.0 | 3.0–4.5 | 4.5–6.0 | 6.0% |       |
| Patient number                    | 617   | 21 | 161 | 226 | 145 | 64 |        |
| Percentage of man (man/woman)    | 44.2 (273/343) | 28.6 (6/15) | 33.5 (54/107) | 43.0 (97/129) | 52.4 (76/69) | 64.1 (41/23) | <0.0001 |
| Follow-up year (years)            | 3.2 | 2.9 | 2.7 | 2.5 | 3.3 | 2.7 | 3.2 | 3.0 | 3.1 | 2.9 | 3.1 | 3.4 | 0.9281 |
| Patient starting RRT during follow-up (%) | 35 (5.7) | 0 (0) | 4 (2.5) | 12 (5.3) | 11 (7.6) | 8 (12.5) | 0.0272 |
| Age at initial eGFR measurement (years) | 46.8 | 12.7 | 53.7 | 14.8 | 53.3 | 13.4 | 48.2 | 12.0 | 41.7 | 7.8 | 34.8 | 8.3 | <0.0001 |
| Age at initial TKV measurement (years) | 47.1 | 12.7 | 53.8 | 15.5 | 53.8 | 13.3 | 48.6 | 12.0 | 41.8 | 8.0 | 35.7 | 8.4 | <0.0001 |
| Initial eGFR (mL/min/1.73 m²)     | 65.1 | 26.2 | 69.0 | 30.3 | 67.2 | 23.8 | 64.5 | 26.6 | 63.1 | 26.4 | 65.0 | 28.6 | 0.6605 |
| Last eGFR (mL/min/1.73 m²)        | 57.2 | 26.6 | 64.4 | 30.4 | 60.0 | 24.7 | 55.9 | 26.0 | 54.7 | 26.0 | 58.0 | 32.1 | 0.2720 |
| Initial TKV (mL)                  | 1,478 | 1,022 | 40.3 | 101 | 821 | 341 | 1,363 | 619 | 1,923 | 890 | 2,900 | 1,640 | <0.0001 |
| Initial HTKV (mL/m)               | 955 | 613 | 251 | 64 | 510 | 215 | 832 | 384 | 1,153 | 536 | 1,724 | 995 | <0.0001 |
| eHTKV-α (K = 130) (%/year)        | 3.983 | 1.601 | 1.160 | 0.288 | 2.430 | 0.395 | 3.709 | 0.431 | 5.143 | 0.430 | 7.148 | 1.105 | <0.0001 |
| Height (cm)                       | 164.7 | 9.2 | 160.4 | 6.8 | 161.9 | 8.9 | 164.4 | 9.3 | 167.1 | 8.7 | 168.9 | 8.1 | <0.0001 |
| Weight (kg)                       | 60.6 | 11.9 | 55.2 | 10.8 | 56.6 | 10.4 | 60.4 | 12.2 | 63.5 | 11.3 | 65.5 | 12.2 | <0.0001 |
| Age at diagnosis of ADPKD (years) | 39.3 | 12.8 | 47.5 | 17.7 | 45.7 | 13.1 | 41.1 | 12.0 | 34.3 | 8.4 | 26.5 | 7.8 | <0.0001 |
| Age at initial manifestation (years) | 38.3 | 11.9 | 41.4 | 16.9 | 43.9 | 12.3 | 40.9 | 11.0 | 34.3 | 8.5 | 26.8 | 7.9 | <0.0001 |
| Age at hypertension onset (years)  | 40.8 | 11.3 | 55.4 | 12.5 | 46.7 | 12.0 | 44.0 | 9.7 | 36.4 | 8.2 | 28.6 | 5.5 | <0.0001 |
| Presence of hypertension (%)      | 67.9 | 42.9 | 55.9 | 71.7 | 73.1 | 81.3 | 0.0002 |
| Presence of family history (%)    | 75.7 | 61.9 | 83.2 | 69.0 | 77.2 | 81.3 | 0.0009 |

Mayo Class was divided using eHTKV-α (K = 130 mL/m). RRT, renal replacement therapy; SD, standard deviation; eGFR, estimated glomerular filtration rate; TKV, total kidney volume; HTKV, height-adjusted TKV; eHTKV-α, estimated height-adjusted total kidney volume growth rate α (%/year); Mayo Class, Mayo Imaging Classification. p-values for numeric variables were derived from ANOVA and those for categorical variables were derived from χ² test (Pearson).
dated using the bootstrap method. The Institutional Review Boards of Kyorin University (1046-04) and Juntendo University (19-148) approved this study and all patients provided informed consent.

Study Participants
A total of 617 standard-of-care patients with typical ADPKD and baseline age above 19 who visited Kyorin University Hospital (388 patients) and Juntendo University Hospital (229 patients) between April 2007 and December 2018 were analyzed. Subjects under the age of 20 were excluded because the equation for eHTKV-α is derived from the analysis of adult data [6, 17]. Patients who started RRT prior to the initial visit or who received invasive therapy or tolvaptan to reduce the renal volume at any time were excluded from the analysis.

Measurement of TKV and eGFR and the Definition of ESRD
TKV was measured using stereology by MRI [20]. eGFR was calculated using serum Cr according to the Isotope Dilution Mass Spectrometry and Modification of Diet in Renal Disease (IDMS-MDRD) with the Japanese coefficient [21]. ESRD was defined by starting RRT (kidney transplantation or dialysis) during the observation period, and the case was truncated in renal survival analyses.

eHTKV-α Calculations
Using the equation \( \text{HTKV at age } t = K(1 + \text{eHTKV-α/(100)^t} \), eHTKV-α was calculated with age measured to 2 digits after the decimal point. \( K = 130 \text{ mL/m} \) and \( K = 150 \text{ mL/m} \) were used [17].

Estimation of Preliminary eHTKV-α Cutoff Values to Predict CKD Stage 5
The eGFR at age 60, 65, and 70 was estimated using individual eGFR regression lines. Preliminary cutoff values of eHTKV-α to

Table 2. Validation of the area under the time-dependent ROC curve

| Factor | Censored age | AUC of entire data set | Validated AUC |
|--------|--------------|------------------------|---------------|
|        |              |                        | mean ± SE     | 95% CI        |
| eHTKV-α (K = 130) | 60 | 0.8187 | 0.882±0.049 | 0.786–0.978   |
|        | 65 | 0.8233 | 0.892±0.038 | 0.817–0.966   |
|        | 70 | 0.7982 | 0.876±0.045 | 0.788–0.965   |
| eHTKV-α (K = 150) | 60 | 0.8256 | 0.876±0.051 | 0.776–0.975   |
|        | 65 | 0.8271 | 0.884±0.040 | 0.806–0.963   |
|        | 70 | 0.8017 | 0.866±0.047 | 0.775–0.958   |

| Factor | Censored age | Difference in AUC | Difference in validated AUC |
|--------|--------------|-------------------|-----------------------------|
|        |              |                   | mean ± SE                  | 95% CI               |
| eHTKV-α (K = 130)–eHTKV-α(K = 150) | 60 | −0.0069 | 0.006±0.033 | 0.001–0.011   |
|        | 65 | −0.0039 | 0.008±0.040 | 0.001–0.015   |
|        | 70 | −0.0035 | 0.010±0.004 | 0.002–0.018   |

The area under the ROC curve was calculated using time-dependent ROC analysis and was validated using the Uno method [23]. eHTKV-α, estimated height-adjusted total kidney volume growth rate α (%/year); SE, standard error; CI, confidence interval; AUC, area under the ROC curve; ROC, receiver operating characteristic.

Fig. 1. eHTKV-α well predicts ESRD. The AUC of eHTKV-α was estimated using the entire data set (Table 2). AUC, area under the ROC curve; eHTKV-α, estimated height-adjusted total kidney volume growth rate α (%/year).
predict CKD stage 5 (eGFR <15 mL/min/1.73 m²) at censored ages were estimated using ROC analysis.

Evaluation of Accuracy of eHTKV-α to Predict ESRD

The accuracy of eHTKV-α to predict ESRD for censored ages was evaluated using the area under time-dependent ROC (AUC) [22] and validated using Uno's Concordance Statistic [23].

Estimation and Validation of eHTKV-α Cutoff Points to Predict High-Risk ESRD

The mean renal survival was compared according to the subgroups divided by a 0.5%/year interval of eHTKV-α around preliminary cutoff values. As a standard definition of rapidly progressive disease was absent, the cutoff point for high-risk ESRD was defined as follows: (1) mean renal survival ≤70 years at an eHTKV-α ≥ the cutoff point, (2) difference in mean renal survival ≥5 years between 2 subgroups divided by cutoff points, and (3) smaller cutoff points of eHTKV-α, in each K-value. eHTKV-α, estimated height-adjusted total kidney volume growth rate (%/year); SE, standard error. p-values were derived from the log-rank and Wilcoxon tests.

Table 3. Comparison of renal survival among subgroups divided by eHTKV-α around preliminary cutoff values

| Comparison subgroups divided by initial eHTKV-α (%/year) | Truncated/censored number | Renal survival (years) |
|----------------------------------------------------------|---------------------------|------------------------|
|                                                          | K = 130                   | K = 150                |
|                                                          | mean ± SE                 | p-value                |
|                                                          | mean ± SE                 | p-value                |
| a Four comparison subgroups                              |                           |                        |
| ≤2.0                                                     | 0/51                      | 0/81                   | –                      |
| 2.0<⋯≤3.0                                                | 4/127                     | 6/148                  | 71.9±0.3               | <0.0001 |
| 3.0<⋯≤4.0                                                | 8/149                     | 8/142                  | 74.6±0.9               | 74.3±0.9 | 1.0       |
| 4.0<                                                    | 23/255                    | 21/211                 | 63.5±1.0               | <0.0001 |
| ≤2.5                                                    | 2/104                     | 3/146                  | 67.8±0.3               | 62.1±1.3 | 0.001     |
| 2.5<⋯≤3.5                                                | 6/154                     | 7/158                  | 71.5±0.5               | 75.3±0.7 | 0.001     |
| 3.5<⋯≤4.5                                                | 8/134                     | 6/136                  | 73.2±1.3               | 67.2±0.7 | 0.001     |
| 4.5<                                                    | 19/190                    | 19/142                 | 57.7±0.7               | 56.7±0.8 | 0.001     |
| ≤3.0                                                    | 4/178                     | 6/229                  | 72.1±0.2               | <0.0001 |
| 3.0<⋯≤4.0                                                | 8/149                     | 8/142                  | 74.6±0.9               | 74.3±0.9 | 1.0       |
| 4.0<                                                    | 6/128                     | 6/115                  | 66.8±0.9               | 65.0±1.5 | 1.2       |
| 5.0<                                                    | 17/127                    | 15/96                  | 56.2±1.0               | 55.6±1.2 | 1.2       |
| ≤3.5                                                    | 8/258                     | 10/304                 | 71.7±0.3               | <0.0001 |
| 3.5<⋯≤4.5                                                | 8/134                     | 6/136                  | 73.2±1.3               | 67.2±0.7 | 0.001     |
| 4.5<⋯≤5.5                                                | 6/100                     | 10/82                  | 55.9±0.4               | 58.0±0.9 | 0.001     |
| 5.5<                                                    | 13/90                     | 9/60                   | 55.2±1.4               | 50.7±0.8 | 0.001     |
| b Two comparison subgroups                              |                           |                        |
| ≤3.0                                                    | 4/178                     | 6/229                  | 72.1±0.2               | <0.0001 |
| 3.0<                                                    | 31/404                    | 29/353                 | 71.4±0.9               | 70.9±1.0 | 0.1       |
| ≤3.5                                                    | 8/258                     | 10/304                 | 71.7±0.3               | <0.0001 |
| 3.5<                                                    | 27/324                    | 25/278                 | 69.6±1.3               | 64.0±0.9 | 0.001     |
| ≤4.0                                                    | 12/327                    | 14/371                 | 75.5±0.4               | <0.0001 |
| 4.0<                                                    | 23/255                    | 21/211                 | 63.5±1.0               | 62.1±1.3 | 1.3       |
| ≤4.5                                                    | 16/392                    | 16/440                 | 75.2±0.4               | <0.0001 |
| 4.5<                                                    | 19/190                    | 19/142                 | 57.7±0.7               | 56.7±0.8 | 0.001     |
| Total                                                   | 35/582                    | 73.6±0.5               | 73.6±0.5               | 0.001     |

Results were derived from Kaplan-Meier estimates using eHTKV-α, calculated using K = 130 mL/m and K = 150 mL/m. Comparison subgroups were divided around an eHTKV-α, of 4%/year, which was a preliminary cutoff value of the initial eHTKV-α, to predict eGFR, decline to 15 mL/min/1.73 m² at age 60 to 70 (online suppl. Table 2). Cutoff points printed in italic and bold were selected based on: (1) the mean renal survival ≤70 years at an eHTKV-α ≥ the cutoff point, (2) difference in mean renal survival ≥5 years between 2 subgroups divided by cutoff points, and (3) smaller cutoff points of eHTKV-α, in each K-value. eHTKV-α, estimated height-adjusted total kidney volume growth rate (%/year); SE, standard error. p-values were derived from the log-rank and Wilcoxon tests.
eHTKV-α to predict ESRD for censored ages were validated using the bootstrap method.

**Statistical Analysis**

Normally distributed variables are expressed as the mean ± standard error or standard deviation. Differences between groups were tested using the χ² test for categorical variables and a general linear model with covariates as factors for continuous variables.

Regression lines of eGFR against age of the subgroups divided by the initial eHTKV-α were calculated using a mixed-effect model with age, groups, and sex as fixed effects, and with age × groups and age × sex as interaction effects. The mean renal survival was calculated using Kaplan-Meier analysis and multivariate hazard ratios adjusted by sex were calculated using Cox's proportional hazards model. AUC was estimated using time-dependent ROC analysis and was validated using Uno's method [23].

Performance characteristics of eHTKV-α to predict ESRD for cutoff points and for censored ages were evaluated using time-dependent ROC analysis and was validated using Uno's method [23].

Cutoff values of initial eHTKV-α to predict CKD stage 5 at censored ages were estimated from 4.0 to 4.3%/year (online suppl. Table 2). As the accuracy of the initial eHTKV-α to predict CKD stage 5 was weak (AUC = 0.63), these cutoff values were used as preliminary.

Cutoff Values of eHTKV-α to Predict High-Risk ESRD

Renal survival probability curves are illustrated for 4 subgroups divided by the initial eHTKV-α (≤3.0, 3.0–4.0, 4.0–5.0, and 5.0≤) (online suppl. Fig. 3). Renal survival probability was less than 50% for subjects with eHTKV-α >4.0%/year at age 60–70. This result is in accordance with the censored ages used in this study.

The mean renal survival for all subjects was 73.6 years (Table 3), and 70 years was selected as a limit of the mean renal survival for subgroups with a high-risk of ESRD. In the subgroups with a lower limit of eHTKV-α of 4.0%/year (K = 130 mL/m) or 3.5%/year (K = 150 mL/m), the mean renal survival was less than 70 years (Table 3A). In the subgroups with an eHTKV-α in these ranges, the mean renal survival was approximately 12 years shorter than that of the other subjects (Table 3B). Among cutoff points shown in Table 3, an eHTKV-α of 4%/year (K = 130 mL/m) or 3.5%/year (K = 150 mL/m) was the lowest value and considered as a cutoff point for high-risk ESRD.

Multivariate hazard ratios of ESRD adjusted by the sex of the subgroup with high-risk ESRD versus the next lower eHTKV-α subgroup, or versus the other subjects were 7 to 8- or 10 to 11-times higher, respectively (p < 0.0001) (online suppl. Table 3).

Cutoff Points of eHTKV-α to Predict CKD Stage 5

The eGFR slope became steeper from Mayo Class 1A to 1E. The pattern of decline in eGFR was not noticeably different between K = 130 mL/m and K = 150 mL/m (online suppl. Table 1; Fig. 2).

Cutoff values of initial eHTKV-α to predict CKD stage 5 at censored ages were estimated from 4.0 to 4.3%/year (online suppl. Table 2). As the accuracy of the initial eHTKV-α to predict CKD stage 5 was weak (AUC = 0.63), these cutoff values were used as preliminary.

Accuracy of eHTKV-α to Predict ESRD

The validated AUC of eHTKV-α to predict ESRD for censored age 65 was 0.89 ± 0.04 and 0.88 ± 0.04 for K = 130 and K = 150, respectively (Table 2). The high AUC shows that eHTKV-α proposes good prediction of ESRD.

The validated AUC of K = 130 mL/m was slightly higher than that of K = 150 mL/m for censored ages (Table 2). However, when calculated using entire data set, the AUC was slightly higher for K = 150 mL/m than for K = 130 mL/m for censored ages (Table 2; Fig 1) and for all age (p = 0.0693, see online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000511797).

Take these results into together, there is no significant difference in AUC between K = 130 mL/m and K = 150 mL/m.

### Results

**Clinical Characteristics of Participants**

The demographic characteristics of the participants are summarized according to Mayo Class (Table 1). During mean (±standard deviation) 3.2 (±2.6) years follow-up, eGFR decreased 8.0 ± 11.9 mL/min/1.73 m². Totally 35 patients started RRT during follow-up. The disease was more severe with a higher initial eHTKV-α. Earlier diagnosis, earlier onset of disease manifestations, and higher proportion of starting RRT were noted in higher eHTKV-α subgroups.

**Accuracy of eHTKV-α to Predict ESRD**

The validated AUC of eHTKV-α to predict ESRD for censored age 65 was 0.89 ± 0.04 and 0.88 ± 0.04 for K = 130 and K = 150, respectively (Table 2). The high AUC shows that eHTKV-α proposes good prediction of ESRD.

The validated AUC of K = 130 mL/m was slightly higher than that of K = 150 mL/m for censored ages (Table 2). However, when calculated using entire data set, the AUC was slightly higher for K = 150 mL/m than for K = 130 mL/m for censored ages (Table 2; Fig 1) and for all age (p = 0.0693, see online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000511797). Take these results into together, there is no significant difference in AUC between K = 130 mL/m and K = 150 mL/m.
Discussion

Genic and allelic heterogeneity [3], possible modifying genetic factors [24], and environmental factors, such as treatment of hypertension [25], salt intake [26], and possible toxic water [27], are associated with phenotypic variability (Fig. 2). Although there is wide variation in phenotypic expression and diverse factors that affect the phenotype, individual renal disease progression is associated with the kidney volume growth rate [5, 6, 28, 29].

The annual growth rate of HtTKV is estimated by eHTKV-α, which is calculated based on a single measure-
ment of kidney volume and height [6, 17]. eHTKV-α is a good renal prognostic biomarker [6], which is confirmed by a high validated AUC of eHTKV-α for predicting ESRD in this study (Table 2; Fig. 1). The validated AUC of eHTKV-α is higher than that of the Predicting Renal Outcome in Polycystic Kidney Disease (PRO-PKD) score at age 65 (0.84 ± 0.02) [30].

Eligibility criteria can be described by a single eHTKV-α value without indexing for age and body size, since eHTKV-α value contains these items in itself, and without using additional risk factors such as genotype, age-dependently decreasing eGFR, eGFR slope, TKV slope, or age-dependently increasing incidence of symptoms. Patients do not need to repeat clinical tests or wait several years until judgment of eligibility.

In the ERA-EDTA guidelines [15], patients aged 40–50 years with an eGFR >60 mL/min/1.73 m² or patients aged 30–40 years with an eGFR >90 mL/min/1.73 m² are considered slow progressors. Among the remaining subjects, at least one of the following criteria is required to diagnose rapid progression: (1) a confirmed annual eGFR decline of ≥5 mL/min/1.73 m² in 1 year or ≥2.5 mL/min/1.73 m² over a period of 5 years; (2) a TKV increase of >5%/year by repeated measurements (preferably 3 or more); (3) Mayo Class 1C, 1D, or 1E; (4) kidney length assessed by ultrasound of >16.5 cm in patients aged <45 years; and/or (5) having a truncating PKD1 mutation in conjunction with PRO-PKD score >6.

The eGFR is not appropriate predictor for individual renal prognosis even with an index for age because (1) during ages 20–40, it remains within comparable levels with slow progressors (>90 mL/min/1.73 m²) and starts to decline at a rate comparable with moderate to rapid progressors [6, 29]; (2) even in subjects aged 30–40 with an eGFR >90 mL/min/1.73 m², ESRD developed in a substantial number [16]; (3) it declines in a nonlinear pattern in a considerable fraction [19]; and (4) the eGFR is acutely influenced by nonrenal factors such as overhydration, dehydration, and heavy exercise and by transient renal factors such as renal infection and urinary tract obstruction. These factors limit the reliability of eGFR and eGFR slope in prognostication of renal survival.

The annual TKV slope varies considerably and actual TKV growth patterns fluctuate year to year, which look like measurement errors [29]. The TKV growth rate estimated by eHTKV-α is more stable than the TKV growth rate estimated using 2 TKV observations because the TKV measurement fluctuation is spread over 20 or more years in the former case but is only spread over 1 or 2 years in the latter [17, 29].

The PRO-PKD score uses genetic and clinical data. Genetic analysis is not generally used for clinical practice, and clinical manifestation is not used for subjects younger than 35 years or those missing clinical data [30]. The lower accuracy of PRO-PKD score than eHTKV-α might be due to the weak association of ADPKD genotype than
the rate of kidney volume growth with the development of ESRD (Fig. 2) [31].

In the practical guide of the US group, Mayo Class 1C, 1D, and 1E are classified as rapidly progressing disease and are recommended for tolvaptan treatment [16]. The difference between the US guidelines and this study is the inclusion of subjects with an eHTKV-α of 3.0–3.5%/year (K = 150 mL/m) into rapid progressors in the US guidelines. In the Canadian guidelines, tolvaptan is recommended for Mayo Class 1C to 1E. However, additional risk factors, such as an annual decrease in eGFR of >2.5 mL/min/1.73 m² and/or increase in TKV of >5% per year, are required only for patients classified into 1C [18]. Additional conditions for 1C in Canadian guidelines may be unnecessary when the cutoff point of eHTKV-α is changed from 3.0 to 3.5%/year (K = 150 mL/m).

Approximately 93.4% (K = 130 mL/m) or 94.6% (K = 150 mL/m) of the subjects likely progress to ESRD by age 65 are distinguished as the high-risk ESRD subgroup (true positive) (Table 5). High sensitivity is preferable because this cutoff point disregards the few (5–7%) patients who progress to ESRD from the indication of tolvaptan treatment.

A relatively low specificity suggests that only 45.6–47.8% (for K = 130 and age 65 in Table 5) of subjects who do not progress to ESRD by 65 years is included to non-high-risk ESRD group. Rest of subjects (52.2–54.4%) who do not progress to ESRD by age 65 is included to high-risk group (high false-positive rate). However, the eGFR decreases at a rate of more than 2.0 mL/min/1.73 m² per year in subjects of this category (online suppl. Table 1) and ESRD may develop after 65 years. Beneficial treatment effects of tolvaptan were confirmed in the population within this eHTKV-α limit [17, 32]. In addition, the subjects included in high-risk category by these cutoff points are less than half of total subjects (45% at K = 130 and 49% at K = 150). Inclusion of approximately half of patients for slowing the rate of renal functional decline by medical treatment seems to be permissible.

A single eHTKV-α value is advantageous for prognosticating ESRD because of the following points: (1) the accuracy of eHTKV-α in predicting ESRD is high. (2) It is calculated by a single measurement of TKV, and an index of age or body size is not required. (3) Limitations of using risk factor(s), such as eGFR, slope of eGFR, TKV, and TKV slope, can be avoided. (4) The measurement fluctuation of eHTKV-α is smaller than that of the TKV slope obtained by 2 or more measurements of TKV.

In conclusion, an initially measured eHTKV-α of ≥4.0%/year (K = 130 mL/m) or ≥3.5%/year (K = 150 mL/m) defines high-risk ESRD. Without additional conditions, a single eHTKV-α cutoff point can identify adult subjects that are most likely to benefit from tolvaptan.

Acknowledgements

We thank the hundreds of patients who gave informed consent to the study and Ms. Ayako Hirao for secretary assistance. Dr. Horie was supported by Grant-in-Aid for Scientific Research (18K09151).

Statement of Ethics

This study was approved by the IRB of Kyorin University (1046-04) and Juntendo University (19-148).

Conflict of Interest Statement

Dr. Higashihara reports consulting fees from Sanofi Genzyme and grant support from Otsuka Pharmaceuticals and Taisho Pharmaceutical. Dr. Horie reports consulting fees from Sanofi, Endowment Chair, grant support from Otsuka Pharmaceuticals, and Honorarium from Chugai. Dr. Muto reports grant support from Otsuka Pharmaceuticals.

Author Contributions

Research idea and study design: E.H., S.H., and S.M.; data acquisition: S.M., H.K., M.T., T.Y., S.T., K.Y., T.Y., and H.F.; data analysis/interpretation: E.H., S.K., and T.F.; statistical analysis: T.F. and E.H.; each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

References

1. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008 Oct; 359(14):1477–85.
2. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016 May; 67(5):792–810.
3. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013 May; 24(6):1006–13.
1 Horie S, Mochizuki T, Muto S, Hanaoka K, Morita K, Nitta K, et al. Erratum to: Evidence-based clinical practice guidelines for autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2015 Nov;10(11):1994–9.

2 Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016 Mar;31(3):337–48.

3 Irazabal MV, Rangel LJ, Bergstralh EJ, Oshima SI, Harmon AJ, Sundsbak J, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan;26(1):160–72.

4 Grantham JJ, Chapman AB, Devuyst O, Gansevoort RT, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec;367(25):2407–18.

5 Pharmaceuticals and Medical Devices Agency [Internet]. Tokyo: Prescribing Information (in Japanese); [cited 2020 July 30]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/180078.2139011D1022_1_08.

6 Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2015 Jul;372(7):1053–62.

7 Grantham JJ, Chapman AB, Devuyst O, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May;354(20):2122–30.

8 Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2005 May;352(20):2047–56.

9 Phelps SE, Orskov B, Kramer A, Meijer E, Meijer E, et al. Rationale for early treatment of conventional treatments for chronic kidney disease. N Engl J Med. 2015 Jul;372(3):239–49.

10 Horie S, Mochizuki T, Muto S, Hanaoka K, Morita K, Nitta K, et al. Erratum to: Evidence-based clinical practice guidelines for autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2015 Nov;10(11):1994–9.

11 Irazabal MV, Rangel LJ, Bergstralh EJ, Oshima SI, Harmon AJ, Sundsbak J, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan;26(1):160–72.

12 European Medicines Agency [Internet]. Amsterdum: EU Summary of product characteristics finar epar product information; [cited 2020 July 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/moban-epar-product-information_en.pdf.

13 Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017 Nov;377(20):1930–42.

14 US Food and Drug Administration [Internet]. Maryland: Highlights of prescribing information JYNARQUE; [cited 2020 July 30]. Available from: https://www.otsuka-us.com/media/static/JYNARQUE-PI.pdf.

15 Grantham JJ, Chapman AB, Devuyst O, Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016 Mar;31(3):337–48.

16 Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. Practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018 Oct;29(10):2458–70.

17 Higashihara E, Fukuhara H, Ouyang J, Lee J, Nutahara K, Tanbo M, et al. Estimation of changes in kidney volume growth rate in autosomal dominant polycystic kidney disease. Kidney Int Reports. 2020; 5: 1459–1471.

18 Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, et al. Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can J Kidney Health Dis. 2018 Oct;5.

19 Brosnahan GM, Abebe KZ, Moore CG, Rahbargi-Oskoui FF, Bae KT, Grantham JJ, et al. Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016 Mar;31(3):337–48.

20 Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, et al. Erratum to: Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol. 2016 Aug;20(4):510–9.